

**NOTICE OF SCHEDULE 13G FILING WITH THE UNITED STATES SECURITIES EXCHANGE
COMMISSION**

Valley Cottage, New York, September 19, 2007 – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) hereby notifies that it has just become aware that on September 18, 2007, a Schedule 13G Filing was made with the United States Securities Exchange Commission (“US SEC”) regarding notification of a 7.89% beneficial ownership of the Company’s Ordinary Shares.

The filing can be found on the US SEC’s EDGAR website at
http://www.sec.gov/Archives/edgar/data/1023549/000119380507002410/e602614_13g-xtlbio.txt

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225